Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory multiple myeloma.
Multiple Myeloma in Relapse|Multiple Myeloma Progression
BIOLOGICAL: anti-CD19/BCMA CAR-T cells|DRUG: Fludarabine|DRUG: Cyclophosphamide
Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0, Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0, 6 months
Overall remission rate defined by the standard response criteria for myeloma for each arm, Overall remission rate defined by the standard response criteria for myeloma for each arm, 8 weeks|Duration of CAR-positive T cells in circulation, Duration of CAR-positive T cells in circulation, 6 months
Primary Objectives

1. To determine the feasibility ad safety of anti-CD19/BCMA CAR-T cells in treating patients with BCMA-positive multiple myeloma.

Secondary Objectives

1. To access the efficacy of anti-CD19/BCMA CAR-T cells in patients with multiple myeloma.
2. To determine in vivo dynamics and persistency of anti-CD19/BCMA CAR-T cells.